Last reviewed · How we verify
continue cozaar
Cozaar (losartan) blocks angiotensin II receptors on blood vessels and tissues, causing vasodilation and reducing blood pressure.
Cozaar (losartan) blocks angiotensin II receptors on blood vessels and tissues, causing vasodilation and reducing blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes, Heart failure with reduced ejection fraction.
At a glance
| Generic name | continue cozaar |
|---|---|
| Sponsor | University of Pittsburgh |
| Drug class | Angiotensin II receptor antagonist (ARB) |
| Target | AT1 receptor (Angiotensin II Type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor antagonist (ARB) that selectively blocks the AT1 receptor, preventing angiotensin II from binding and triggering vasoconstriction and aldosterone release. This leads to decreased peripheral vascular resistance, lower blood pressure, and reduced sodium and water retention. It is commonly used as a first-line antihypertensive agent and for renal protection in diabetic patients.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes
- Heart failure with reduced ejection fraction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Headache
Key clinical trials
- Losartan + Sunitinib in Treatment of Osteosarcoma (PHASE1)
- Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer (PHASE2)
- Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer (PHASE2)
- Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction (PHASE4)
- Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (PHASE1)
- An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension (PHASE3)
- Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors (PHASE1)
- Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- continue cozaar CI brief — competitive landscape report
- continue cozaar updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI